Treatment of Pediatric Type 2 Diabetes

Smith, Jennifer D.; Mills, Elizabeth; Carlisle, Sara E.

doi:10.1177/1060028016655179

Cited by 14 publications

(13 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This increase in Sertoli cell number leads to a duplication of testicular volume from 2 to 4 mL, clinically reflected in Tanner stage 2 (Rey et al 2016). At this point, it is important to remind that the incidence of both T2D and obesity in children has risen at staggering rates and that MET has started to be used in pediatric population at the time when Sertoli cells are proliferating (Brufani et al 2013, Adeyemo et al 2015, Smith et al 2016. If MET alters postnatal Sertoli cell proliferation in mammalian testis, it should be considered a warning about possible deleterious effects on future fertility when this drug is used in children.…”

Section: Introductionmentioning

confidence: 99%

Metformin counteracts the effects of FSH on rat Sertoli cell proliferation

Rindone¹,

Gorga²,

Regueira³

et al. 2018

Reproduction

View full text Add to dashboard Cite

Metformin (MET) is one of the most widely used anti-hyperglycemic agents for treating patients with type 2 diabetes and it has started to be used in pediatric population at ages when Sertoli cells are still proliferating. It is well known that follicle-stimulating hormone (FSH) is the major Sertoli cell mitogen. The aim of the study is to investigate a possible effect of MET, which has been shown to have anti-proliferative properties, on FSH regulation of postnatal Sertoli cell proliferation and on the molecular mechanisms involved in this regulation. The present study was performed in eight-day-old rat Sertoli cell cultures. The results obtained show that MET in the presence of FSH increases phosphorylated acetyl-CoA carboxylase and decreases phosphorylated p70S6K levels. Moreover, we show that MET decreases FSH-stimulated Sertoli cell proliferation, and this decrease is accompanied by a reduction in FSH-stimulated and expression and an increase in cell cycle inhibitor expression. Altogether, these results suggest that MET can, at least in part, counteract the effect of FSH on postnatal Sertoli cell proliferation.

show abstract

Section: Introductionmentioning

confidence: 99%

Metformin counteracts the effects of FSH on rat Sertoli cell proliferation

Rindone¹,

Gorga²,

Regueira³

et al. 2018

Reproduction

View full text Add to dashboard Cite

show abstract

“…Elle permet de réduire le taux d'HbA1c de 1 % à 2 %, n'entraînant que des effets secondaires minimes (p. ex. nausée, diarrhée) ; elle ne provoque pas d'hypoglycémie puisqu'elle augmente la sensibilité à l'insuline et n'agit donc pas sur la production d'insuline [49] . Un autre agent, le glimépiride, apporte une réduction comparable de l'HbA1c chez l'adolescent, mais est associé à une prise pondérale.…”

Section: Prise En Charge Complémentaireà L'alimentation Et Aux Habituunclassified

Diabète de type 2 chez les jeunes : stratégies nutritionnelles pour la prévention et la prise en charge

Hulst¹,

Bonin²,

Nakouzi³

et al. 2018

Nutrition Science en évolution

View full text Add to dashboard Cite

Tous droits réservés © Ordre professionnel des diététistes du Québec, 2018 Ce document est protégé par la loi sur le droit d'auteur. L'utilisation des services d'Érudit (y compris la reproduction) est assujettie à sa politique d'utilisation que vous pouvez consulter en ligne. https://apropos.erudit.org/fr/usagers/politique-dutilisation/ Cet article est diffusé et préservé par Érudit.Érudit est un consortium interuniversitaire sans but lucratif composé de l

show abstract

“…Insulin and metformin are the only two FDA-approved medications for diabetes in patients younger than 18 years old, but other medications such as thiazolidindiones and incretins have been used with success as off-label agents in some patients(7, 23). The TODAY study (7) demonstrated that the addition of rosiglitazone enhances the efficacy of metformin, improving rates of glycemic control.…”

Section: Nonsurgical Treatment Options For T2dmentioning

confidence: 99%

Bariatric Surgery for Adolescents with Type 2 Diabetes: an Emerging Therapeutic Strategy

Stefater

Inge

2017

Curr Diab Rep

View full text Add to dashboard Cite

Purpose of Review Type 2 diabetes (T2D) is a growing public health problem in youth, but conventional treatments are often insufficient to treat this disease and its comorbidities. We review evidence supporting an emerging role for bariatric surgery as a treatment for adolescent T2D. Recent Findings Paralleling what has been seen in adult patients, bariatric surgery dramatically improves glycemic control in patients with T2D. In fact, remission of T2D has been observed in as many as 95–100% of adolescents with diabetes after bariatric surgery, particularly vertical sleeve gastrectomy (VSG) and Roux-en-Y gastric bypass (RYGB) surgery. This striking outcome may be due to both weight-dependent- and weight-independent factors and recent studies suggest T2D-related comorbidities may also improve after surgery. Summary Bariatric surgery including RYGB and VSG is a powerful therapeutic option for obese adolescents with T2D. Benefits must be weighed against risk for postoperative complications such as nutritional deficiencies, but earlier surgical intervention might lead to more complete metabolic remission in obese patients with T2D.

show abstract

Treatment of Pediatric Type 2 Diabetes

Abstract: Metformin and insulin remain the mainstay of treatment for T2DM in pediatric patients. More robust studies are needed to assist in the provision of evidence-based guidance for the treatment of T2DM in youth.

Cited by 14 publications

References 18 publications

Metformin counteracts the effects of FSH on rat Sertoli cell proliferation

Metformin counteracts the effects of FSH on rat Sertoli cell proliferation

Diabète de type 2 chez les jeunes : stratégies nutritionnelles pour la prévention et la prise en charge

Bariatric Surgery for Adolescents with Type 2 Diabetes: an Emerging Therapeutic Strategy

Contact Info

Product

Resources

About